News

Deal Announcements

3-V Biosciences Secures $30 Million Venture Capital

Monday, August 17, 2009 5:28:00 AM PDT | VentureDeal Staff
Palo Alto, California  --  Biotechnology company 3-V Biosciences has secured $30 million in its second round of institutional venture capital financing.

3-V Biosciences was founded by a number of executives at the Swiss Federal Institute of technology in Zürich, Switzerland.  Host pathway screening began in November, 2007.

New Enterprise Associates led the round, which also included The Column Group and Kleiner Perkins Caufield & Byers.  The company said that the funding would be used for "both exploratory research and early clinical development of the company's lead programs targeting the treatment of respiratory viral infections."

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1